GSK-3: Tricks of the trade for a multi-tasking kinase

Journal of Cell Science

Volumn 116, Issue 7, 2003, Pages 1175-1186

  Doble, Bradley W ^a   Woodgett, James R ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Insulin signalling; Phosphorylation; Protein structure function; Signal transduction; Wnt signalling

Indexed keywords

2 (2,4 DICHLOROPHENYL) 3 (1 METHYL 3 INDOLYL)MALEIMIDE; 2 (3 CHLORO 4 HYDROXYANILINO) 3 (2 NITROPHENYL)MALEIMIDE; 2 [1 (3 AMIDINOTHIOPROPYL) 1H INDOL 3 YL] 3 (1 METHYL 1H INDOL 3 YL)MALEIMIDE; AF 150; ALOISINE; BERYLLIUM; BETA CATENIN; CEVIMELINE; G PROTEIN COUPLED RECEPTOR; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; INDIRUBIN; LITHIUM; MALEIMIDE DERIVATIVE; MUSCARINIC AGENT; PAULLONE DERIVATIVE; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE; SERINE; SONIC HEDGEHOG PROTEIN; TAU PROTEIN; UNCLASSIFIED DRUG; WNT PROTEIN; ZINC DERIVATIVE;

ALZHEIMER DISEASE; CELL ACTIVITY; CELL CULTURE; CELL CYCLE; CELL DEATH; CELL PROLIFERATION; CRYSTAL STRUCTURE; DISEASE ASSOCIATION; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; ENZYME SUBSTRATE; EUKARYOTE; GLYCOGEN METABOLISM; HISTOPATHOLOGY; HUMAN; MITOSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION;

ALZHEIMER DISEASE; ANIMALS; DIABETES MELLITUS; EUKARYOTIC CELLS; GLYCOGEN SYNTHASE KINASE 3; HEDGEHOG PROTEINS; HUMANS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS; SIGNAL TRANSDUCTION; TRANS-ACTIVATORS; WNT PROTEINS; ZEBRAFISH PROTEINS;

ERINACEIDAE; EUKARYOTA;

EID: 0037383322     PISSN: 00219533     EISSN: None     Source Type: Journal    
DOI: 10.1242/jcs.00384     Document Type: Review

References (160)

1. Ali, A., Hoeflich, K. P. and Woodgett, J. R. (2001). Glycogen synthase kinase-3: properties, functions, and regulation. Chem. Rev. 101, 2527-2540.
2. Amit, S., Hatzubai, A., Birman, Y., Andersen, J. S., Ben-Shushan, E., Mann, M., Ben-Neriah, Y. and Alkalay, I. (2002). Axin-mediated CKI phosphorylation of beta-catenin at Ser 45: a molecular switch for the Wnt pathway. Genes Dev. 16, 1066-1076.
3. Armstrong, J. L., Bonavaud, S. M., Toole, B. J. and Yeaman, S. J. (2001). Regulation of glycogen synthesis by amino acids in cultured human muscle cells. J. Biol. Chem. 276, 952-956.
4. Aza-Blanc, P., Ramirez-Weber, F. A., Laget, M. P., Schwartz, C. and Kornberg, T. B. (1997). Proteolysis that is inhibited by hedgehog targets Cubitus interruptus protein to the nucleus and converts it to a repressor. Cell 89, 1043-1053.
5. Ballou, L. M., Tian, P. Y., Lin, H. Y., Jiang, Y. P. and Lin, R. Z. (2001). Dual regulation of glycogen synthase kinase-3beta by the alpha1A-adrenergic receptor. J. Biol. Chem. 276, 40910-40916.
6. Barker, N., Morin, P. J. and Clevers, H. (2000). The Yin-Yang of TCF/beta-catenin signaling. Adv. Cancer Res. 77, 1-24.
7. Bax, B., Carter, P. S., Lewis, C., Guy, A. R., Bridges, A., Tanner, R., Pettman, G., Mannix, C., Culbert, A. A., Brown, M. J. et al. (2001). The structure of phosphorylated GSK-3beta complexed with a peptide, FRATtide, that inhibits beta-catenin phosphorylation. Structure (Camb) 9, 1143-1152.
8. Beals, C. R., Sheridan, C. M., Turck, C. W., Gardner, P. and Crabtree, G. R. (1997). Nuclear export of NF-ATc enhanced by glycogen synthase kinase-3. Science 275, 1930-1934.
9. Beg, A. A., Sha, W. C., Bronson, R. T., Ghosh, S. and Baltimore, D. (1995). Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-kappa B. Nature 376, 167-170.
10. Bellon, S., Fitzgibbon, M. J., Fox, T., Hsiao, H. M. and Wilson, K. P. (1999). The structure of phosphorylated p38gamma is monomeric and reveals a conserved activation-loop conformation. Structure Fold. Des. 7, 1057-1065.
11. Benjamin, W. B., Pentyala, S. N., Woodgett, J. R., Hod, Y. and Marshak, D. (1994). ATP citrate-lyase and glycogen synthase kinase-3 beta in 3T3-L1 cells during differentiation into adipocytes. Biochem J. 300, 477-482.
12. Bhat, R. V., Shanley, J., Correll, M. P., Fieles, W. E., Keith, R. A., Scott, C. W. and Lee, C. M. (2000). Regulation and localization of tyrosine216 phosphorylation of glycogen synthase kinase-3beta in cellular and animal models of neuronal degeneration. Proc. Natl. Acad. Sci. USA 97, 11074-11079.
13. Bijur, G. N. and Jope, R. S. (2001). Proapoptotic stimuli induce nuclear accumulation of glycogen synthase kinase-3 beta. J. Biol. Chem. 276, 37436-37442.
14. Bourouis, M., Moore, P., Ruel, L., Grau, Y., Heitzler, P. and Simpson, P. (1990). An early embryonic product of the gene shaggy encodes a serine/threonine protein kinase related to the CDC28/cdc2+ subfamily. EMBO J. 9, 2877-2884.
15. Boyle, W. J., Smeal, T., Defize, L. H., Angel, P., Woodgett, J. R., Karin, M. and Hunter, T. (1991). Activation of protein kinase C decreases phosphorylation of c-Jun at sites that negatively regulate its DNA-binding activity. Cell 64, 573-584.
16. Brady, M. J., Bourbonais, F. J. and Saltiel, A. R. (1998). The activation of glycogen synthase by insulin switches from kinase inhibition to phosphatase activation during adipogenesis in 3T3-L1 cells. J. Biol. Chem. 273, 14063-14066.
17. Brantjes, H., Barker, N., van Es, J. and Clevers, H. (2002). TCF: Lady Justice casting the final verdict on the outcome of Wnt signalling. Biol. Chem. 383, 255-261.
18. Breton, J. J. and Chabot-Fletcher, M. C. (1997). The natural product hymenialdisine inhibits interleukin-8 production in U937 cells by inhibition of nuclear factor-kappaB. J. Pharmacol. Exp. Ther 282, 459-466.
19. Brown, N. R., Noble, M. E., Endicott, J. A. and Johnson, L. N. (1999). The structural basis for specificity of substrate and recruitment peptides for cyclin-dependent kinases. Nat. Cell Biol. 1, 438-443.
20. Canagarajah, B. J., Khokhlatchev, A., Cobb, M. H. and Goldsmith, E. J. (1997). Activation mechanism of the MAP kinase ERK2 by dual phosphorylation. Cell 90, 859-869.
21. Carmichael, J., Sugars, K. L., Bao, Y. and Rubinsztein, D. C. (2002). GSK-3beta inhibitors prevent cellular polyglutamine toxicity caused by the Huntington's disease mutation. J. Biol. Chem. 277, 33791-33798.
22. Chen, G., Huang, L. D., Jiang, Y. M. and Manji, H. K. (1999). The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3. J. Neurochem. 72, 1327-1230.
23. Chu, B., Soncin, F., Price, B. D., Stevenson, M. A. and Calderwood, S. K. (1996). Sequential phosphorylation by mitogen-activated protein kinase and glycogen synthase kinase 3 represses transcriptional activation by heat shock factor-1. J. Biol. Chem. 271, 30847-30857.
24. Coghlan, M. P., Culbert, A. A., Cross, D. A., Corcoran, S. L., Yates, J. W., Pearce, N. J., Rausch, O. L., Murphy, G. J., Carter, P. S., Roxbee Cox, L. et al. (2000). Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem. Biol. 7, 793-803.
25. Cohen, P., Alessi, D. R. and Cross, D. A. (1997). PDK1, one of the missing links in insulin signal transduction? FEBS Lett. 410, 3-10.
26. Cross, D. A., Alessi, D. R., Cohen, P., Andjelkovich, M. and Hemmings, B. A. (1995). Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378, 785-789.
27. Cross, D. A., Culbert, A. A., Chalmers, K. A., Facci, L., Skaper, S. D. and Reith, A. D. (2001). Selective small-molecule inhibitors of glycogen synthase kinase-3 activity protect primary neurones from death. J. Neurochem. 77, 94-102.
28. Dajani, R., Fraser, E., Roe, S. M., Young, N., Good, V., Dale, T. C. and Pearl, L. H. (2001). Crystal structure of glycogen synthase kinase 3 beta: structural basis for phosphate-primed substrate specificity and autoinhibition. Cell 105, 721-732.
29. Damiens, E., Baratte, B., Marie, D., Eisenbrand, G. and Meijer, L. (2001). Anti-mitotic properties of indirubin-3′-monoxime, a CDK/GSK-3 inhibitor: induction of endoreplication following prophase arrest. Oncogene 20, 3786-37897.
30. De Ferrari, G. V. and Inestrosa, N. C. (2000). Wnt signaling function in Alzheimer's disease. Brain Res Rev 33, 1-12.
31. De Sarno, P., Li, X. and Jope, R. S. (2002). Regulation of Akt and glycogen synthase kinase-3beta phosphorylation by sodium valproate and lithium. Neuropharmacology 43, 1158-1164.
32. Dent, P., Campbell, D. G., Hubbard, M. J. and Cohen, P. (1989). Multisite phosphorylation of the glycogen-binding subunit of protein phosphatase-1G by cyclic AMP-dependent protein kinase and glycogen synthase kinase-3. FEBS Lett. 248, 67-72.
33. Dent, P., Lavoinne, A., Nakielny, S., Caudwell, F. B., Watt, P. and Cohen, P. (1990). The molecular mechanism by which insulin stimulates glycogen synthesis in mammalian skeletal muscle. Nature 348, 302-308.
34. Detera-Wadleigh, S. D. (2001). Lithium-related genetics of bipolar disorder. Ann. Med. 33, 272-285.
35. Diehl, J. A., Cheng, M., Roussel, M. F. and Sherr, C. J. (1998). Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev. 12, 3499-3511.
36. Dierick, H. and Bejsovec, A. (1999). Cellular mechanisms of wingless/Wnt signal transduction. Curr. Top. Dev. Biol. 43, 153-190.
37. Ding, V. W., Chen, R. H. and McCormick, F. (2000). Differential regulation of glycogen synthase kinase 3beta by insulin and Wnt signaling. J. Biol. Chem. 275, 32475-32481.
38. Eldar-Finkelman, H. (2002). Glycogen synthase kinase 3: an emerging therapeutic target. Trends Mol. Med. 8, 126-132.
39. Eldar-Finkelman, H. and Krebs, E. G. (1997). Phosphorylation of insulin receptor substrate 1 by glycogen synthase kinase 3 impairs insulin action. Proc. Natl. Acad. Sci. USA 94, 9660-9664.
40. Embi, N., Rylatt, D. B. and Cohen, P. (1980). Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. Eur. J. Biochem. 107, 519-527.
41. Fang, X., Yu, S., Tanyi, J. L., Lu, Y., Woodgett, J. R. and Mills, G. B. (2002). Convergence of multiple signaling cascades at glycogen synthase kinase 3: Edg receptor-mediated phosphorylation and inactivation by lysophosphatidic acid through a protein kinase C-dependent intracellular pathway. Mol. Cell. Biol. 22, 2099-2110.
42. Fang, X., Yu, S. X., Lu, Y., Bast, R. C., Jr, Woodgett, J. R. and Mills, G. B. (2000). Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A. Proc. Natl. Acad. Sci. USA 97, 11960-11965.
43. Farr, G. H., 3rd, Ferkey, D. M., Yost, C., Pierce, S. B., Weaver, C. and Kimelman, D. (2000). Interaction among GSK-3, GBP, axin, and APC in Xenopus axis specification. J. Cell Biol. 148, 691-702.
44. Ferkey, D. M. and Kimelman, D. (2002). Glycogen synthase kinase-3 beta mutagenesis identifies a common binding domain for GBP and Axin. J. Biol. Chem. 277, 16147-16152.
45. Fiol, C. J., Mahrenholz, A. M., Wang, Y., Roeske, R. W. and Roach, P. J. (1987). Formation of protein kinase recognition sites by covalent modification of the substrate. Molecular mechanism for the synergistic action of casein kinase II and glycogen synthase kinase 3. J. Biol. Chem. 262, 14042-14048.
46. Fiol, C. J., Haseman, J. H., Wang, Y. H., Roach, P. J., Roeske, R. W., Kowalczuk, M. and DePaoli-Roach, A. A. (1988). Phosphoserine as a recognition determinant for glycogen synthase kinase-3: phosphorylation of a synthetic peptide based on the G-component of protein phosphatase-1. Arch. Biochem. Biophys. 267, 797-802.
47. Fiol, C. J., Wang, A., Roeske, R. W. and Roach, P. J. (1990). Ordered multisite protein phosphorylation. Analysis of glycogen synthase kinase 3 action using model peptide substrates. J. Biol. Chem. 265, 6061-6065.
48. Fiol, C. J., Williams, J. S., Chou, C. H., Wang, Q. M., Roach, P. J. and Andrisani, O. M. (1994). A secondary phosphorylation of CREB341 at Ser129 is required for the cAMP-mediated control of gene expression. A role for glycogen synthase kinase-3 in the control of gene expression. J. Biol. Chem. 269, 32187-32193.
49. Forlenza, O. V., Spink, J. M., Dayanandan, R., Anderton, B. H., Olesen, O. F. and Lovestone, S. (2000). Muscarinic agonists reduce tau phosphorylation in non-neuronal cells via GSK-3beta inhibition and in neurons. J. Neural. Transm. 107, 1201-1212.
50. Frame, S. and Cohen, P. (2001). GSK3 takes centre stage more than 20 years after its discovery. Biochem. J. 359, 1-16.
51. Frame, S., Cohen, P. and Biondi, R. M. (2001). A common phosphate binding site explains the unique substrate specificity of GSK3 and its inactivation by phosphorylation. Mol. Cell 7, 1321-1327.
52. Franca-Koh, J., Yeo, M., Fraser, E., Young, N. and Dale, T. C. (2002). The regulation of glycogen synthase Kinse-3 nuclear export by Frat/GBP. J. Biol. Chem. 277, 43844-43848.
53. Fraser, E., Young, N., Dajani, R., Franca-Koh, J., Ryves, J., Williams, R. S., Yeo, M., Webster, M. T., Richardson, C., Smalley, M. J. et al. (2002). Identification of the Axin and Frat binding region of glycogen synthase kinase-3. J. Biol. Chem. 277, 2176-2185.
54. Freemantle, S. J., Portland, H. B., Ewings, K., Dmitrovsky, F., DiPetrillo, K., Spinella, M. J. and Dmitrovsky, E. (2002). Characterization and tissue-specific expression of human GSK-3-binding proteins FRAT1 and FRAT2. Gene 291, 17-27.
55. Gao, Z. H., Seeling, J. M., Hill, V., Yochum, A. and Virshup, D. M. (2002). Casein kinase I phosphorylates and destabilizes the beta-catenin degradation complex. Proc. Natl. Acad. Sci. USA 99, 1182-1187.
56. Ghosh, S. and Karin, M. (2002). Missing pieces in the NF-kappaB puzzle. Cell 109, S81-96.
57. Gould, T. D. and Manji, H. K. (2002). The Wnt signaling pathway in bipolar disorder. Neuroscientist 8, 497-511.
58. Grimes, C. A. and Jope, R. S. (2001). The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog. Neurobiol. 65, 391-426.
59. Hagen, T. and Vidal-Puig, A. (2002). Characterisation of the phosphorylation of beta-catenin at the GSK-3 priming site Ser45. Biochem. Biophys. Res. Commun. 294, 324-328.
60. Hagen, T., di Daniel, E., Culbert, A. A. and Reith, A. D. (2002). Expression and characterization of GSK-3 mutants and their effect on beta-catenin phosphorylation in intact cells. J. Biol. Chem. 277, 23330-23335.
61. Hall, A. C., Brennan, A., Goold, R. G., Cleverley, K., Lucas, F. R., Gordon-Weeks, P. R. and Salinas, P. C. (2002). Valproate regulates GSK-3-mediated axonal remodeling and synapsin I clustering in developing neurons. Mol. Cell. Neurosci. 20, 257-270.
62. Hanger, D. P., Hughes, K., Woodgett, J. R., Brion, J. P. and Anderton, B. H. (1992). Glycogen synthase kinase-3 induces Alzheimer's disease-like phosphorylation of tau: generation of paired helical filament epitopes and neuronal localisation of the kinase. Neurosci Lett. 147, 58-62.
63. Hartigan, J. A. and Johnson, G. V. (1999). Transient increases in intracellular calcium result in prolonged site-selective increases in Tau phosphorylation through a glycogen synthase kinase 3beta-dependent pathway. J. Biol. Chem. 274, 21395-21401.
64. Hartigan, J. A., Xiong, W. C. and Johnson, G. V. (2001). Glycogen synthase kinase 3beta is tyrosine phosphorylated by PYK2. Biochem. Biophys. Res. Commun. 284, 485-489.
65. Hers, I., Tavare, J. M. and Denton, R. M. (1999). The protein kinase C inhibitors bisindolylmaleimide I (GF 109203x) and IX (Ro 31-8220) are potent inhibitors of glycogen synthase kinase-3 activity. FEBS Lett. 460, 433-436.
66. Hinoi, T., Yamamoto, H., Kishida, M., Takada, S., Kishida, S. and Kikuchi, A. (2000). Complex formation of adenomatous polyposis coli gene product and axin facilitates glycogen synthase kinase-3 beta-dependent phosphorylation of beta-catenin and down-regulates beta-catenin. J. Biol. Chem. 275, 34399-34406.
67. Hoeflich, K. P., Luo, J., Rubie, E. A., Tsao, M. S., Jin, O. and Woodgett, J. R. (2000). Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature 406, 86-90.
68. Huelsken, J. and Behrens, J. (2002). The Wnt signalling pathway. J. Cell Sci. 115, 3977-3978.
69. Hughes, K., Ramakrishna, S., Benjamin, W. B. and Woodgett, J. R. (1992). Identification of multifunctional ATP-citrate lyase kinase as the alpha-isoform of glycogen synthase kinase-3. Biochem. J. 288, 309-314.
70. Hughes, K., Nikolakaki, E., Plyte, S. E., Totty, N. F. and Woodgett, J. R. (1993). Modulation of the glycogen synthase kinase-3 family by tyrosine phosphorylation. EMBO J. 12, 803-808.
71. Ikeda, S., Kishida, S., Yamamoto, H., Murai, H., Koyama, S. and Kikuchi, A. (1998). Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3beta and beta-catenin and promotes GSK-3beta-dependent phosphorylation of beta-catenin. EMBO J. 17, 1371-1384.
72. Ilouz, R., Kaidanovich, O., Gurwitz, D. and Eldar-Finkelman, H. (2002). Inhibition of glycogen synthase kinase-3beta by bivalent zinc ions: insight into the insulin-mimetic action of zinc. Biochem. Biophys. Res. Commun. 295, 102-106.
73. Ingham, P. W. and McMahon, A. P. (2001). Hedgehog signaling in animal development: paradigms and principles. Genes Dev. 15, 3059-3087.
74. Jang, M. K., Goo, Y. H., Sohn, Y. C., Kim, Y. S., Lee, S. K., Kang, H., Cheong, J. and Lee, J. W. (2001). Ca2+/calmodulin-dependent protein kinase IV stimulates nuclear factor-kappa B transactivation via phosphorylation of the p65 subunit. J. Biol. Chem. 276, 20005-20010.
75. Jho, E., Lomvardas, S. and Costantini, F. (1999). A GSK3beta phosphorylation site in axin modulates interaction with beta-catenin and Tcf-mediated gene expression. Biochem. Biophys. Res. Commun 266, 28-35.
76. Jia, J., Amanai, K., Wang, G., Tang, J., Wang, B. and Jiang, J. (2002). Shaggy/GSK3 antagonizes Hedgehog signalling by regulating Cubitus interruptus. Nature 416, 548-452.
77. Johnson, R. L., Rothman, A. L., Xie, J., Goodrich, L. V., Bare, J. W., Bonifas, J. M., Quinn, A. G., Myers, R. M., Cox, D. R., Epstein, E. H., Jr et al. (1996). Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science 272, 1668-1671.
78. Kaidanovich, O. and Eldar-Finkelman, H. (2002). The role of glycogen synthase kinase-3 in insulin resistance and Type 2 diabetes. Expert Opin. Ther. Targets 6, 555-561.
79. Khaled, M., Larribere, L., Bille, K., Aberdam, E., Ortonne, J. P., Ballotti, R. and Bertolotto, C. (2002). Glycogen synthase kinase 3b is activated by cAMP and plays an active role in the regulation of melanogenesis. J. Biol. Chem. 277, 33690-33697.
80. Kim, L., Harwood, A. and Kimmel, A. R. (2002). Receptor-dependent and tyrosine phosphatase-mediated inhibition of GSK3 regulates cell fate choice. Dev. Cell 3, 523-532.
81. Kim, L., Liu, J. and Kimmel, A. R. (1999). The novel tyrosine kinase ZAK1 activates GSK3 to direct cell fate specification. Cell 99, 399-408.
82. Kirschenbaum, F., Hsu, S. C., Cordell, B. and McCarthy, J. V. (2001). Glycogen synthase kinase-3beta regulates presenilin 1 C-terminal fragment levels. J. Biol. Chem. 276, 30701-30707.
83. Kishida, M., Hino, S., Michiue, T., Yamamoto, H., Kishida, S., Fukui, A., Asashima, M. and Kikuchi, A. (2001). Synergistic activation of the Wnt signaling pathway by Dv1 and casein kinase Iepsilon. J. Biol. Chem. 276, 33147-33155.
84. Klein, P. S. and Melton, D. A. (1996). A molecular mechanism for the effect of lithium on development. Proc. Natl. Acad. Sci. USA 93, 8455-8459.
85. Knockaert, M., Wieking, K., Schmitt, S., Leost, M., Grant, K. M., Mottram, J. C., Kunick, C. and Meijer, L. (2002). Intracellular targets of Paullones. Identification following affinity purification on immobilized inhibitor. J. Biol. Chem. 277, 25493-25501.
86. Krause, U., Bertrand, L., Maisin, L., Rosa, M. and Hue, L. (2002). Signalling pathways and combinatory effects of insulin and amino acids in isolated rat hepatocytes. Eur. J. Biochem. 269, 3742-3750.
87. Leclerc, S., Garnier, M., Hoessel, R., Marko, D., Bibb, J. A., Snyder, G. L., Greengard, P., Biernat, J., Wu, Y. Z., Mandelkow, E. M. et al. (2001). Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors? J. Biol. Chem. 276, 251-260.
88. Lee, E., Salic, A. and Kirschner, M. W. (2001). Physiological regulation of [beta]-catenin stability by Tcf3 and CK1epsilon. J. Cell Biol. 154, 983-993.
89. Leost, M., Schultz, C., Link, A., Wu, Y. Z., Biernat, J., Mandelkow, E. M., Bibb, J. A., Snyder, G. L., Greengard, P., Zaharevitz, D. W. et al. (2000). Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25. Eur. J. Biochem. 267, 5983-5994.
90. Lesort, M., Jope, R. S. and Johnson, G. V. (1999). Insulin transiently increases tau phosphorylation: involvement of glycogen synthase kinase-3beta and Fyn tyrosine kinase. J. Neurochem. 72, 576-584.
91. Li, M., Wang, X., Meintzer, M. K., Laessig, T., Birnbaum, M. J. and Heidenreich, K. A. (2000). Cyclic AMP promotes neuronal survival by phosphorylation of glycogen synthase kinase 3beta. Mol. Cell. Biol. 20, 9356-9363.
92. Li, Q., van Antwerp, D., Mercurio, F., Lee, K. F., and Verma, I. M. (1999). Severe liver degeneration in mice lacking the IkappaB kinase 2 gene. Science 284, 321-325.
93. Li, X., Bijur, G. N. and Jope, R. S. (2002). Glycogen synthase kinase-3beta, mood stabilizers, and neuroprotection. Bipolar Disord. 4, 137-144.
94. Li, Y., Bharti, A., Chen, D., Gong, J. and Kufe, D. (1998). Interaction of glycogen synthase kinase 3beta with the DF3/MUC1 carcinoma-associated antigen and beta-catenin. Mol. Cell. Biol. 18, 7216-7224.
95. Liu, C., Li, Y., Semenov, M., Han, C., Baeg, G. H., Tan, Y., Zhang, Z., Lin, X. and He, X. (2002). Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell 108, 837-847.
96. Lochhead, P, A., Coghlan, M., Rice, S. Q. and Sutherland, C. (2001). Inhibition of GSK-3 selectively reduces glucose-6-phosphatase and phosphatase and phosphoenolypyruvate carboxykinase gene expression. Diabetes 50, 937-946.
97. Maccioni, R. B., Munoz, J. P. and Barbeito, L. (2001). The molecular bases of Alzheimer's disease and other neurodegenerative disorders. Arch. Med. Res. 32, 367-381.
98. Manji, H. K., Moore, G. J. and Chen, G. (1999). Lithium at 50: have the neuroprotective effects of this unique cation been overlooked? Biol. Psychiatry 46, 929-940.
99. Manoukian, A. S. and Woodgett, J. R. (2002). Role of glycogen synthase kinase-3 in cancer: regulation by Wnts and other signaling pathways. Adv. Cancer Res. 84, 203-229.
100. Martinek, S., Inonog, S., Manoukian, A. S. and Young, M. W. (2001). A role for the segment polarity gene shaggy/GSK-3 in the Drosophila circadian clock. Cell 105, 769-779.
101. Martinez, A., Alonso, M., Castro, A., Perez, C. and Moreno, F. J. (2002a). First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease. J. Med. Chem. 45, 1292-1299.
102. Martinez, A., Castro, A., Dorronsoro, I. and Alonso, M. (2002b). Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation. Med. Res. Rev. 22, 373-384.
103. Mattson, M. P. (2001). Neuronal death and GSK-3beta: a tau fetish? Trends Neurosci. 24, 255-256.
104. McKay, R. M., Peters, J. M. and Graff, J. M. (2001). The casein kinase I family in Wnt signaling. Dev. Biol. 235, 388-396.
105. Meijer, L., Thunnissen, A. M., White, A. W., Garnier, M., Nikolic, M., Tsai, L. H., Walter, J., Cleverley, K. E., Salinas, P. C., Wu, Y. Z. et al. (2000). Inhibition of cyclin-dependent kinases, GSK-3beta and CK1 by hymenialdisine, a marine sponge constituent. Chem. Biol. 7, 51-63.
106. Mettey, Y., Gompel, M., Thomas, V., Garnier, M., Leost, M., Ceballos-Picot, I., Noble, M., Endicott, J., Vierfond, J. M. and Meijer, L. (2003). Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects. J Med. Chem. 46, 222-236.
107. Miller, J. R. (2002). The Wnts. Genome Biol. 3, REVIEWS3001.
108. Morfini, G., Szebenyi, G., Elluru, R., Ratner, N. and Brady, S. T. (2002). Glycogen synthase kinase 3 phosphorylates kinesin light chains and negatively regulates kinesin-based motility. EMBO J. 21, 281-293.
109. Mukai, F., Ishiguro, K., Sano, Y. and Fujita, S. C. (2002). Alternative splicing isoform of tau protein kinase I/glycogen synthase kinase 3beta. J. Neurochem. 81, 1073-1083.
110. Murai, H., Okazaki, M. and Kikuchi, A. (1996). Tyrosine dephosphorylation of glycogen synthase kinase-3 is involved in its extracellular signal-dependent inactivation. FEBS Lett. 392, 153-160.
111. Novak, A. and Dedhar, S. (1999). Signaling through beta-catenin and Lef/Tcf. Cell Mol. Life Sci. 56, 523-537.
112. Palacino, J. J., Murphy, M. P., Murayama, O., Iwasaki, K., Fujiwara, M., Takashima, A., Golde, T. E. and Wolozin, B. (2001). Presenilin 1 regulates beta-catenin-mediated transcription in a glycogen synthase kinase-3-independent fashion. J. Biol. Chem. 276, 38563-38569.
113. Park, I. K., Roach, P., Bondor, J., Fox, S. P. and DePaoli-Roach, A. A. (1994). Molecular mechanism of the synergistic phosphorylation of phosphatase inhibitor-2. Cloning, expression, and site-directed mutagenesis of inhibitor-2. J. Biol. Chem. 269, 944-954.
114. Plyte, S. E., O'Donovan, E., Woodgett, J. R. and Harwood, A. J. (1999). Glycogen synthase kinase-3 (GSK-3) is regulated during Dictyostelium development via the serpentine receptor cAR3. Development 126, 325-333.
115. Polakis, P. (1997). The adenomatous polyposis coli (APC) tumor suppressor. Biochim. Biophys. Acta 1332, F127-F147.
116. Polakis, P. (2000). Wnt signaling and cancer. Genes Dev. 14, 1837-1851.
117. Polakis, P. (2002). Casein Kinase 1: A Wnt'er of disconnect. Curr. Biol. 12, R499.
118. Price, M. A. and Kalderon, D. (2002). Proteolysis of the Hedgehog signaling effector Cubitus interruptus requires phosphorylation by Glycogen Synthase Kinase 3 and Casein Kinase 1. Cell 108, 823-835.
119. Pulverer, B. J., Fisher, C., Vousden, K., Littlewood, T., Evan, G. and Woodgett, J. R. (1994). Site-specific modulation of c-Myc cotransformation by residues phosphorylated in vivo. Oncogene 9, 59-70.
120. Rothwarf, D. M. and Karin, M. (1999). The NF-kappa B activation pathway: a paradigm in information transfer from membrane to nucleus. Sci STKE 1999, RE1.
121. Rubinfeld, B., Albert, I., Porfiri, E., Fiol, C., Munemitsu, S. and Polakis, P. (1996). Binding of GSK3beta to the APC-beta-catenin complex and regulation of complex assembly. Science 272, 1023-1026.
122. Ruiz i Altaba, A. (1999) Gli proteins and Hedgehog signaling: development and cancer. Trends Genet. 15, 418-425.
123. Ryves, W. J. and Harwood, A. J. (2001). Lithium inhibits glycogen synthase kinase-3 by competition for magnesium. Biochem. Biophys. Res. Commun. 280, 720-725.
124. Ryves, W. J., Dajani, R., Pearl, L. and Harwood, A. J. (2002). Glycogen synthase kinase-3 inhibition by lithium and beryllium suggests the presence of two magnesium binding sites. Biochem. Biophys. Res. Commun. 290, 967-972.
125. Saito, Y., Vandenheede, J. R. and Cohen, P. (1994). The mechanism by which epidermal growth factor inhibits glycogen synthase kinase 3 in A431 cells. Biochem. J. 303, 27-31.
126. Sakanaka, C. (2002). Phosphorylation and regulation of beta-catenin by casein kinase I epsilon. J. Biochem. (Tokyo) 132, 697-703.
127. Sayas, C. L., Avila, J. and Wandosell, F. (2002). Glycogen synthase kinase-3 is activated in neuronal cells by galpha 12 and galpha 13 by rho-independent and rho-dependent mechanisms. J. Neurosci. 22, 6863-6875.
128. Schwabe, R. F. and Brenner, D. A. (2002). Role of glycogen synthase kinase-3 in TNF-alpha-induced NF-kappaB activation and apoptosis in hepatocytes. Am. J. Physiol. Gastrointest. Liver Physiol. 283, G204-G211.
129. Schwarz-Romond, T., Asbrand, C., Bakkers, J., Kuhl, M., Schaeffer, H. J., Huelsken, J., Behrens, J., Hammerschmidt, M. and Birchmeier, W. (2002). The ankyrin repeat protein Diversin recruits Casein kinase Iepsilon to the beta-catenin degradation complex and acts in both canonical Wnt and Wnt/JNK signaling. Genes Dev. 16, 2073-2084.
130. Sears, R., Nuckolls, F., Haura, E., Taya, Y., Tamai, K. and Nevins, J. R. (2000). Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev. 14, 2501-2514.
131. Seidensticker, M. J. and Behrens, J. (2000). Biochemical interactions in the wnt pathway. Biochim. Biophys. Acta 1495, 168-182.
132. Sharpe, C., Lawrence, N. and Martinez Arias, A. (2001). Wnt signalling: a theme with nuclear variations. Bioessays 23, 311-318.
133. Siegfried, E. and Perrimon, N. (1994). Drosophila wingless: a paradigm for the function and mechanism of Wnt signaling. Bioessays 16, 395-404.
134. Siegfried, E., Perkins, L. A., Capaci, T. M. and Perrimon, N. (1990). Putative protein kinase product of the Drosophila segment-polarity gene zeste-white3. Nature 345, 825-829.
135. Singh, L. P., Denslow, N. D. and Wahba, A. J. (1996). Modulation of rabbit reticulocyte guanine nucleotide exchange factor activity by casein kinases 1 and 2 and glycogen synthase kinase 3. Biochemistry 35, 3206-3212.
136. Smalley, M. J. and Dale, T. C. (1999). Wnt signalling in mammalian development and cancer. Cancer Metastasis Rev. 18, 215-230.
137. Smith, D. G., Buffet, M., Fenwick, A. E., Haigh, D., Ife, R. J., Saunders, M., Slingsby, B. P., Stacey, R. and Ward, R. W. (2001). 3-Anilino-4-arylmaleimides: potent and selective inhibitors of glycogen synthase kinase-3 (GSK-3). Bioorg. Med. Chem. Lett. 11, 635-639.
138. Stambolic, V., Ruel, L. and Woodgett, J. R. (1996). Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr. Biol. 6, 1664-1668.
139. Steiner, M. R., Holtsberg, F. W., Keller, J. N., Mattson, M. P. and Steiner, S. M. (2000). Lysophosphatidic acid induction of neuronal apoptosis and necrosis. Ann. N Y Acad. Sci. 905, 132-141.
140. Sumoy, L., Kiefer, J. and Kimelman, D. (1999). Conservation of intracellular Wnt signaling components in dorsal-ventral axis formation in zebrafish. Dev. Genes Evol. 209, 48-58.
141. Taipale, J. and Beachy, P. A. (2001). The Hedgehog and Wnt signalling pathways in cancer. Nature 411, 349-354.
142. Takeda, K., Takemoto, C., Kobayashi, I., Watanabe, A., Nobukuni, Y., Fisher, D. E. and Tachibana, M. (2000). Ser298 of MITF, a mutation site in Waardenburg syndrome type 2, is a phosphorylation site with functional significance. Hum. Mol. Genet. 9, 125-132.
143. Tanji, C., Yamamoto, H., Yorioka, N., Kohno, N., Kikuchi, K. and Kikuchi, A. (2002). A-kinase anchoring protein AKAP220 binds to glycogen synthase kinase-3beta (GSK-3beta) and mediates protein kinase A-dependent inhibition of GSK-3beta. J. Biol. Chem. 277, 36955-36961.
144. ter Haar, E., Coll, J. T., Austen, D. A., Hsiao, H. M., Swenson, L. and Jain, J. (2001). Structure of GSK3beta reveals a primed phosphorylation mechanism. Nat. Struct. Biol. 8, 593-596.
145. Terruzzi, I., Allibardi, S., Bendinelli, P., Maroni, P., Piccoletti, R., Vesco, F., Samaja, M. and Luzi, L. (2002). Amino acid- and lipid-induced insulin resistance in rat heart: molecular mechanisms. Mol. Cell. Endocrinol. 190, 135-145.
146. Thomas, G. M., Frame, S., Goedert, M., Nathke, I., Polakis, P. and Cohen, P. (1999). A GSK3-binding peptide from FRAT1 selectively inhibits the GSK3-catalysed phosphorylation of axin and beta-catervin. FEBS Lett. 458, 247-251.
147. van Noort, M., Meeldijk, J., van der Zee, R., Destree, O. and Clevers, H. (2002). Wnt signaling controls the phosphorylation status of beta-catenin. J. Biol. Chem. 277, 17901-17905.
148. Wang, Q. M., Fiol, C. J., DePaoli-Roach, A. A. and Roach, P. J. (1994). Glycogen synthase kinase-3 beta is a dual specificity kinase differentially regulated by tyrosine and serine/threonine phosphorylation. J. Biol. Chem. 269, 14566-14574.
149. Wang, D., Westerheide, S. D., Hanson, J. L. and Baldwin, A. S., Jr (2000). Tumor necrosis factor alpha-induced phosphorylation of RelA/p65 on Ser529 is controlled by casein kinase II. J. Biol. Chem. 275, 32592-32597.
150. Watcharasit, P., Bijur, G. N., Zmijewski, J. W., Song, L., Zmijewska, A., Chen, X., Johnson, G. V. and Jope, R. S. (2002). Direct, activating interaction between glycogen synthase kinase-3beta and p53 after DNA damage. Proc. Natl. Acad. Sci. USA 99, 7951-7955.
151. Welsh, G. I. and Proud, C. G. (1993). Glycogen synthase kinase-3 is rapidly inactivated in response to insulin and phosphorylates eukaryotic initiation factor eIF-2B. Biochem. J. 294, 625-629.
152. Williams, R. S., Cheng, L., Mudge, A. W. and Harwood, A. J. (2002). A common mechanism of action for three mood-stabilizing drugs. Nature 417, 292-295.
153. Woodgett, J. R. (1990). Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J. 9, 2431-2438.
154. Woodgett, J. R. (2001). Judging a protein by more than its name: GSK-3. Sci STKE 2001, RE12.
155. Woodgett, J. R. and Cohen, P. (1984). Multisite phosphorylation of glycogen synthase. Molecular basis for the substrate specificity of glycogen synthase kinase-3 and casein kinase-II (glycogen synthase kinase-5). Biochim. Biophys. Acta 788, 339-347.
156. Yamamoto, H., Kishida, S., Kishida, M., Ikeda, S., Takada, S. and Kikuchi, A. (1999). Phosphorylation of axin, a Wnt signal negative regulator, by glycogen synthase kinase-3beta regulates its stability. J. Biol. Chem. 274, 10681-10684.
157. Yanagawa, S., Matsuda, Y., Lee, J. S., Matsubayashi, H., Sese, S., Kadowaki, T. and Ishimoto, A. (2002). Casein kinase I phosphorylates the Armadillo protein and induces its degradation in Drosophila. EMBO J. 21, 1733-1742.
158. Yost, C., Farr, G. H., 3rd, Pierce, S. B., Ferkey, D. M., Chen, M. M. and Kimelman, D. (1998). GBP, an inhibitor of GSK-3, is implicated in Xenopus development and oncogenesis. Cell 93, 1031-1041.
159. Yost, C., Torres, M., Miller, J. R., Huang, E., Kimelman, D. and Moon, R. T. (1996). The axis-inducing activity, stability, and subcellular distribution of beta-catenin is regulated in Xenopus embryos by glycogen synthase kinase 3. Genes Dev. 10, 1443-1454.
160. Yuan, H., Mao, J., Li, L. and Wu, D. (1999). Suppression of glycogen synthase kinase activity is not sufficient for leukemia enhancer factor-1 activation. J. Biol. Chem. 274, 30419-30423.